Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment-Reference-Cited by-同舟云学术

Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment

Published:2017-01-31 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Eltahla Auda A.,Leung Preston,Pirozyan Mehdi R.,Rodrigo Chaturaka,Grebely Jason,Applegate Tanya,Maher Lisa,Luciani Fabio,Lloyd Andrew R.,Bull Rowena A.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep41719.pdf

Reference34 articles.

1. Dore, G. J. & Feld, J. J. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin. Infect. Dis. 60, 1829–1836 (2015).

2. Pawlotsky, J.-M. & Hepatitis, C. Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology (2016).

3. Eltahla, A. et al. Analysis of resistance‐associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. J. Viral Hepat. (2016).

4. Applegate, T. L. et al. Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C. Antivir. Ther. 20, 199–208, doi: 10.3851/IMP2821 (2015).

5. Bartels, D. J. et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J. Virol. 87, 1544–1553, doi: 10.1128/JVI.02294-12 (2013).

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences;Pathogens;2024-08-09

2. Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia;Open Forum Infectious Diseases;2024-03-18

3. Looking at the Molecular Target of NS5A Inhibitors throughout a Population Highly Affected with Hepatitis C Virus;Pathogens;2023-05-24

4. Evolution of within-host variants of the hepatitis C virus;Infection, Genetics and Evolution;2022-04

5. Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis;Revista do Instituto de Medicina Tropical de São Paulo;2022